ArticleInflammopharmacology2025
Inhibition of TRPM3 channels in the medial prefrontal cortex mitigates OCD symptoms following traumatic brain injury.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Intranasal 6-OHDA Induces TRPM3-mediated Neuroinflammation in the pVTA: A Preclinical Early-stage Parkinson's Disease Model.Molecular neurobiology · 2026Article
- A novel blood collection technique from the rat thoracic aorta: employing a diaphragm sac as a reservoir.Laboratory animal research · 2026Article
- Recurrent urinary tract infections and psychological burden: mechanisms and integrative perspectives.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Although tumor necrosis factor-alpha (TNF-α) plays an important role in the development of obsessive-compulsive disorder (OCD), the pathogenesis remains unclear. Since transient receptor potential melastatin 3 (TRPM3) channels are activated during inflammatory conditions, crosstalk with TNF-α in the progression of OCD has not been investigated yet. We hypothesize that mild traumatic brain injury (mTBI) stimulates TRPM3 channels, thereby enhancing the level of TNF-α in the medial prefrontal cortex (mPFC), a key brain region implicated in OCD pathogenesis. The closed-head weight-drop method was used for mTBI-induced OCD in mice, and neurological assessment was carried out using rotarod and beam-walk tests. Marble-burying test, open-field test, dark-light emergence test, and nest-building behavior test were performed to examine OCD-like symptoms. The mPFC was isolated, and the TNF-α level and TRPM3 immunoreactivity were estimated using ELISA and immunohistochemistry techniques. Additionally, Golgi-Cox staining and HPLC were performed to quantify dendritic arbor and serotonin content. To validate our hypothesis, mTBI mice were treated with a selective TRPM3 inhibitor naringenin (50 mg/kg) via intraperitoneal route, and all the above parameters were screened. Marble-burying and nest-building behaviors were increased in mTBI mice. However, exploratory behavior and time spend in the light chamber were significantly reduced. Moreover, mTBI increases TNF-α concentration and TRPM3 immunoreactivity, while decreasing dendritic arbor and serotonin content. Notably, naringenin treatment reversed these behavioral, biochemical, and molecular abnormalities. Naringenin may inhibit TRPM3-mediated TNF-α production and serotonin transmission, thereby suppressing OCD symptoms. Thus, we propose a novel therapeutic approach for treating OCD associated with traumatic brain injury.
Indexed as
Identifiers
40372651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.